Erratum: Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical studies and practices · Ethics and Legal Issues in Pediatric Healthcare · Health Systems, Economic Evaluations, Quality of Life
Due to a production error, there was an error in the Conflict of Interest Statement. Instead of “The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.” It should have read “DS is currently employed by company WCG Clinical.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The publisher apologizes for this mistake.
The original article has been updated.